Overexpression of FoxP 1 is a novel biomarker of malignant human pancreatic cancer

Dapeng Qiu,Feng Han,Hao Zhuang,Qingjun Li,Xianzhou Zhang

2016-01-01

Abstract:Recent studies have shown that FOXP3 plays a significant role in the pancreatic cancer cell metastasis, but whether FOXP1 plays a role in mediating tumor metastasis in pancreatic cancer has not been explored. Here, Co-immunoprecipitation assays were utilized to detect that FOXP1 was physically associated with the EMT inducer ZEB2. Most important, CAPAN-1 cells transfected with FOXP1 shRNA displayed a reversed epithelial morphology and reduced the expression of N-cadherin, while increase the expression of E-cadherin, and the PANC-1 cells transfected with FOXP1 displayed the contrary tendency. Transwell invasion assay, as well as colony formation together shown that FOXP1 promoted cell epithelial-mesenchymal transition and tumorigenesis in vitro and in vivo. Endothelial tube formation assays indicated FOXP1 might regulate the angiogenesis of pancreatic cancer through transcriptional activation of VEGF. qChIP, ChIP as well as Luciferase reporter assays suggested FOXP1 binding on the promoter of Ecadherin and VEGF. The changes in the level of protein and RNA implied that suppression of downstream E-cadherin or activation of VEGF was two distinct important mechanisms by which FOXP1 triggered EMT and angiogenesis. Further, patient samples collected shown that FOXP1 was significantly increased in pancreatic cancer samples, and its higher expression is correlated with poor prognosis, worse over all survivals. Together, our experiments revealed the mechanism for FOXP1 in facilitating tumorigenesis, angiogenesis and metastasis of pancreatic cancer cells, suggesting that FOXP1 might be a novel biomarker of malignant human pancreatic cancer and a potential therapeutic target for treating pancreatic cancer.